Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zenith Epigenetics Ltd.

www.zenithepigenetics.com

Latest From Zenith Epigenetics Ltd.

Venture Funding Deals, June 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.

BioPharmaceutical Medical Device

Execs On The Move, September 2014

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

IN VIVO: Deals Shaping The Medical Industry, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet

The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Zenith Epigenetics Corp.
  • Alberta Ltd.
  • RVX Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Zenith Epigenetics Ltd.
  • Senior Management
  • Donald J McCaffrey, Pres. & CEO
    Brad Cann, CFO
    Edward van der Horst, PhD, VP, Discovery Rsch. & Preclinical Dev.
    Sanjay Lakhotia, PhD, CBO
  • Contact Info
  • Zenith Epigenetics Ltd.
    Phone: (587) 390-7865
    300, 4820 Richard Road SW
    Calgary, T3E 6L1
    Canada
UsernamePublicRestriction

Register